Pharming Group (NASDAQ:PHAR) Stock Rating Upgraded by Wall Street Zen

Pharming Group (NASDAQ:PHAR) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Sunday, Wall Street Zen reports.

A number of other equities analysts have also recently weighed in on PHAR. Canaccord Genuity Group increased their price target on Pharming Group from $38.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. HC Wainwright restated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Tuesday, September 22nd. Oppenheimer restated an “outperform” rating on shares of Pharming Group in a report on Wednesday, October 28th. Zacks Research raised shares of Pharming Group from a “strong sell” rating to a “hold” rating in a research report on Friday, October 23rd. Finally, Weiss Ratings raised shares of Pharming Group from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, October 27th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $39.67.

Pharming Group Stock Up 4.1%

PHAR stock opened at $12.73 on Friday. Pharming Group has a one year low of $9.11 and a one year high of $21.34. The firm has a market cap of $901.03 million, a PE ratio of 39.78 and a beta of -0.05. The firm’s 50 day moving average price is $10.73 and its 200-day moving average price is $13.77. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.31 and a current ratio of 3.23.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.09. Pharming Group had a return on equity of 8.70% and a net margin of 6.23%. The company had revenue of $117.60 million during the quarter, compared to analyst estimates of $117.60 million. On average, equities research analysts anticipate that Pharming Group will post 0.34 EPS for the current year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP bought a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group makes up approximately 6.0% of MAC Alpha Capital Management LP’s portfolio, making the stock its 2nd biggest holding. MAC Alpha Capital Management LP owned approximately 3.03% of Pharming Group as of its most recent SEC filing. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.